This article was originally posted on Sept. 1.

Roche last week said that the European Commission has approved the use of Tarceva as a first-line monotherapy for non-small cell lung cancer in patients with EGFR activating mutations.

Roche's diagnostic arm is developing a companion test to identify EGFR-mutation-positive patients for the drug. The company said it expects the CE Mark for the Cobas EGFR Mutation Test before the end of the year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.